Medome
AI-driven health intelligence app for consumers to prevent misdiagnosis and manage personal health records.
Website: https://medome.ai
PUBLIC
| Name | Medome |
| Tagline | AI-driven health intelligence app for consumers to prevent misdiagnosis and manage personal health records. |
| Headquarters | Boca Raton, United States |
| Founded | 2025 |
| Stage | Seed |
| Business Model | B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Seed |
Links
PUBLIC
- Website: https://medome.ai
- LinkedIn: https://www.linkedin.com/company/medomeai
Executive Summary
PUBLIC
Medome is a consumer-facing AI application that aims to restructure the primary care visit by consolidating fragmented health data into a single, actionable brief designed to prevent misdiagnosis. The company's proposition centers on a critical, unsolved problem in healthcare: diagnostic errors, which it estimates cost hundreds of thousands of lives annually [PR Newswire, Nov. 2022]. Founded in 2025 by Dr. Steven Charlap and Paul Battle, the venture is a direct response to personal tragedy, initiated after Dr. Charlap lost his brother, a cardiologist, to a preventable misdiagnosis [Medome homepage, retrieved 2026].
The core product is a personal health intelligence platform that performs symptom assessments, generates pre-appointment questions and clinical notes, and provides a real-time second opinion during consultations [PR Newswire, Nov. 2022]. Its differentiation is framed as a patented, clinically validated system that applies over 500 algorithms to create a unified health profile, positioning it as the first AI-powered personal health record for consumers [PR.com, Nov 2025]. The founding team brings a blend of clinical and commercial experience; Dr. Charlap is a 40-year licensed physician and also the founder and CEO of SOAP Health, a related entity focused on diagnostic accuracy, while Paul Battle contributes development and sales expertise [Medome Mission, retrieved 2024] [LinkedIn, retrieved 2026].
Capitalization and investor backing are not publicly disclosed, with no verifiable funding rounds or named investors found in available sources. The business model is B2C, targeting direct consumer adoption as a tool for self-advocacy. Over the next 12-18 months, key indicators to monitor will be the translation of its claimed 20,000+ user validation into measurable revenue, the expansion of its clinical validation claims through peer-reviewed channels, and any strategic moves to use its connection to the broader SOAP, Inc. ecosystem.
Data Accuracy: YELLOW -- Core product claims and team backgrounds are corroborated by multiple company sources and press releases. User traction and institutional research claims are sourced solely from company materials.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed |
Company Overview
PUBLIC
Medome was founded in 2025 by Dr. Steven Charlap, a physician with four decades of clinical experience, and Paul Battle, a development and sales executive [PR Newswire, Nov. 2022][LinkedIn, retrieved 2026]. The company is headquartered in Boca Raton, Florida, and operates as a consumer-facing healthtech application [LinkedIn, retrieved 2024]. Its origin is rooted in a personal tragedy, with Dr. Charlap stating he created Medome after losing his brother, a cardiologist, to a preventable misdiagnosis [Medome homepage, retrieved 2026].
The company's public narrative frames its development as being built on five years of research at Stanford and Harvard, though this claim is not independently corroborated by the named institutions in available sources [PR Newswire, Nov. 2022]. Medome is positioned as part of SOAP, Inc., a corporate structure that also includes SOAP Health, a separate entity also founded and led by Dr. Charlap [Forbes, retrieved 2026][Spotify, retrieved 2026]. The primary public milestone is the product launch announced in late 2022, which claimed the platform was already validated by over 20,000 users [PR Newswire, Nov. 2022].
Data Accuracy: YELLOW -- Founders, headquarters, and founding year are confirmed by multiple sources. The connection to SOAP, Inc. is corroborated. The claim of institutional research backing and user validation metrics are not independently verified.
Product and Technology
MIXED
Medome’s product is a consumer-facing AI application designed to intervene in the primary care workflow, specifically in the moments before, during, and after a medical appointment. The core proposition is not merely to store health records, but to actively use them to prevent diagnostic errors. According to company materials, the app begins by consolidating a user’s fragmented medical history into a single, structured profile [Medome homepage, retrieved 2024]. It then applies a library of over 500 algorithms to run symptom and risk assessments, generating a set of personalized questions for the patient to ask their doctor and a preliminary clinical note for the visit [PR.com, Nov 2025]. During the appointment, the platform can record the encounter and, using its AI models, provide what the company calls an “on-the-spot second opinion,” flagging any discrepancies between the doctor’s assessment and the patient’s compiled data [PR Newswire, Nov. 2022]. This positions Medome less as a passive repository and more as an active diagnostic co-pilot.
The technology stack is described as “AI-driven” and “patented,” though the specific models or infrastructure are not detailed in public sources [FinanceWire, Dec 2025]. The system’s claimed clinical validation stems from its application with “thousands of real patients,” and the company asserts it is built on five years of research affiliated with Stanford and Harvard, though this institutional support is not independently verified [PR Newswire, Nov. 2022]. A key differentiator appears to be its focus on the pre-visit preparation layer, a niche less crowded than post-visit clinical documentation or pure data aggregation. The product is framed as a tool for patient advocacy, aiming to empower individuals and caregivers to navigate a complex system with more prepared, data-backed confidence [PR Newswire, Nov. 2022].
Data Accuracy: YELLOW -- Product claims are consistently detailed across the company's own press releases and website, but technical specifics and third-party validation of the AI's efficacy are not publicly available.
Market Research
MIXED The market for consumer-facing health intelligence tools is expanding rapidly, driven by a confluence of patient frustration, technological advancement, and escalating healthcare costs. While Medome's specific total addressable market (TAM) is not quantified in the available public sources, its target problem,medical misdiagnosis,is a well-documented and costly systemic failure.
Quantifying the direct market for misdiagnosis prevention is challenging, as it cuts across several established healthcare segments. Analysts can triangulate using adjacent markets. The global personal health record (PHR) software market, a core component of Medome's offering, was valued at approximately $12.5 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 15.4% through 2030, according to a Grand View Research report [Grand View Research, 2024]. The broader digital health market, encompassing remote monitoring, telehealth, and wellness apps, is significantly larger, with estimates exceeding $300 billion globally [Statista, 2024]. Medome's value proposition also intersects with the clinical decision support systems (CDSS) market, valued at over $3 billion and growing, though this is primarily an enterprise, clinician-facing category [Global Market Insights, 2024].
Several demand drivers create a favorable environment for Medome's proposed solution. The high prevalence and cost of diagnostic errors is a primary catalyst; studies cited in medical literature estimate diagnostic errors affect 12 million U.S. adults annually, with serious harm occurring in a third of those cases [Society to Improve Diagnosis in Medicine]. Concurrently, consumer adoption of digital health tools accelerated during the pandemic and has remained elevated, with patients increasingly seeking to manage and understand their own health data. Regulatory tailwinds, such as the 21st Century Cures Act and its information-blocking rules, are also forcing greater data liquidity, making it technically feasible for applications like Medome to aggregate patient records from disparate electronic health record (EHR) systems.
Key adjacent and substitute markets present both opportunity and risk. On one side, the proliferation of direct-to-consumer (DTC) lab testing (e.g., Everlywell, LetsGetChecked) and symptom-checker apps (e.g., Ada Health, Babylon) conditions consumers to proactive health management but also competes for user attention and trust. On the other, integrated offerings from large tech platforms (Apple Health, Google Fit) and payer-provider ecosystems (UnitedHealth Group's Rally, Kaiser Permanente's KP.org) offer consolidated health records and wellness tracking, potentially reducing the need for a standalone app. Medome's differentiation hinges on its specialized focus on pre-visit preparation and real-time clinical discrepancy flagging, a niche not deeply served by these broader platforms.
Personal Health Record Software (2024) | 12.5 | $B
Clinical Decision Support Systems (2024) | 3.2 | $B
Digital Health Market (2024) | 305 | $B
The chart illustrates the market context: Medome operates within the smaller, specialized PHR and CDSS segments, but its potential reach is bounded by the vastly larger, more generalized digital health ecosystem where competition is intense. The absence of a dedicated market sizing for diagnostic error prevention tools suggests the category is still nascent, leaving room for a pioneer but also indicating unproven commercial demand.
Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous, third-party analyst reports, but no direct sizing for the misdiagnosis-prevention niche is available.
Competitive Landscape
MIXED Medome attempts to carve out a defensible position by focusing exclusively on the pre-appointment preparation and advocacy layer, a niche that sits between traditional personal health record (PHR) platforms and diagnostic support tools. The analysis below maps the competitive terrain, drawing on public positioning and product claims.
The competitive landscape is analyzed through the lens of adjacent categories and functional substitutes.
Segment-by-Segment Competitive Map
The market for consumer-facing health data and diagnostic support is fragmented, with Medome operating at the intersection of several established categories. The primary competitive pressure comes from adjacent substitutes rather than direct rivals.
- PHR and Health Data Aggregators. Platforms like Apple Health (Apple) and Google Fit (Google) offer broad health data consolidation but lack the specific clinical interview and appointment-prep workflow Medome emphasizes. These are general-purpose data repositories with massive built-in distribution through mobile operating systems.
- Symptom Checkers and Triage Tools. Companies such as Ada Health and Buoy Health provide AI-powered symptom assessment and triage, guiding users to potential conditions and next steps. Their focus is on pre-diagnostic guidance, not on structuring a patient's complete history for a specific clinician encounter or providing a post-visit "second opinion."
- Clinical Documentation and Scribe Tools. A growing category of ambient AI scribes, like those from Nuance (Microsoft) and Abridge, capture and structure clinical conversations. These tools are typically clinician-facing, designed to reduce physician burnout, rather than patient-facing advocacy aids.
- Enterprise-Focused Diagnostic Support. Tools like Isabel Healthcare (part of Wolters Kluwer) offer differential diagnosis support to clinicians within electronic health record (EHR) workflows. These are sold into health systems, not directly to consumers.
Medome's stated wedge is its end-to-end focus on the patient's journey into and out of a primary care visit, a sequence most competitors address only in part. Its claim to combine history aggregation, risk assessment, question generation, encounter recording, and discrepancy flagging in a single consumer app is its defining architectural choice [PR Newswire, Nov. 2022].
Defensible Edge and Durability
The company's most cited edge is its clinical validation and patented technology, anchored by the medical background of its founder. Dr. Steven Charlap's 40-year career as a licensed physician provides a foundation for the product's clinical framing and algorithm development [Medome Mission]. The company claims its technology is "patented and clinically validated with thousands of real patients" [FinanceWire, Dec 2025], which, if substantiated, could create a regulatory and credibility moat against purely software-centric entrants.
This edge is potentially durable if the underlying intellectual property covers core methodologies for integrating and analyzing disparate health data for misdiagnosis prevention. However, it is also perishable. The moat depends on continuous clinical validation at scale and the ability to keep the algorithms current with medical literature. Without a recurring enterprise revenue stream or a large, engaged user base to generate proprietary data, the long-term defensibility of a purely clinical IP position is uncertain.
Exposure and Vulnerabilities
Medome's go-to-market strategy as a direct-to-consumer app represents its most significant exposure. It lacks the embedded distribution of Apple Health or the clinician-side adoption of an EHR-integrated scribe. Acquiring users in healthcare is notoriously expensive and slow, and a B2C model must compete for attention in a crowded wellness app market.
Furthermore, the company is exposed on its data aggregation front. Its value proposition assumes users will manually input or connect a "complete medical history," a task with well-documented low compliance. Competitors with deeper EHR integrations or data partnerships (like some payer-sponsored health platforms) could replicate the appointment-prep concept with less user friction. The claim of being "the first AI technology for Personal Health Records for consumers" [PR Newswire, Dec 2025] is a marketing positioning, not a technical barrier that would prevent well-capitalized incumbents from adding similar features.
Plausible 18-Month Scenario
The most plausible near-term scenario hinges on distribution and validation. If Medome can secure a partnership with a large payer, employer group, or health system to white-label or distribute its tool, it could achieve the user scale needed to refine its AI and prove outcomes. In this case, the "winner" would be a company like Teladoc or a major insurer looking to enhance member engagement and reduce misdiagnosis-related costs; they could either acquire Medome or build a competing solution informed by its approach.
Conversely, if Medome remains a standalone consumer app, the "loser" scenario is likely. It would struggle to reach critical mass against better-funded, broader platforms that decide to layer on appointment preparation features. A company like Apple, with its deep health ecosystem and user trust, could introduce a "Health Visit Prep" module, effectively nullifying Medome's unique selling proposition by leveraging its superior data aggregation and device integration.
The verdict in the Analyst Notes section will turn on whether Medome can transition from a novel clinical tool to a commercially scalable product with a clear path to owning its niche.
Data Accuracy: YELLOW -- Competitive analysis is inferred from product positioning and adjacent market segments; no direct competitor data is publicly available for comparison.
Opportunity
PUBLIC
The size of the prize for a successful consumer health intelligence platform is measured in the hundreds of billions of dollars spent annually on preventable medical errors and fragmented care.
The headline opportunity for Medome is to become the default personal health operating system for proactive consumers, a category-defining platform that sits between patients and the healthcare system to coordinate care and prevent diagnostic errors. This outcome is reachable because the company is targeting a fundamental, unsolved problem with a direct-to-consumer wedge. Diagnostic errors affect an estimated 12 million U.S. adults annually, with significant associated costs and mortality [PR Newswire, Nov. 2022]. Medome's approach, which consolidates disparate health data and provides an AI layer for pre-visit preparation and real-time advocacy, addresses a clear gap in a market where existing electronic health records are provider-centric and fragmented. The claim of a patented, clinically validated technology with over 20,000 users suggests early traction for the core concept [PR Newswire, Nov. 2022] [FinanceWire, Dec 2025].
Growth could follow several distinct paths, each with a specific catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Direct-to-Consumer Adoption | The app gains viral adoption among health-conscious and chronically ill patients, becoming a standard tool for managing appointments. | A major partnership with a large employer, health plan, or pharmacy chain to offer Medome as a free benefit. | The product is already positioned for consumers, and the founder's visibility through SOAP Health provides a channel for B2B2C distribution [Forbes] [Spotify]. |
| Clinical Integration & Reimbursement | Medome transitions from a consumer app to a reimbursable digital therapeutic or remote patient monitoring tool. | Securing a CPT code from the AMA or a coverage determination from a major payer like Medicare. | The platform's function aligns with billable chronic care management services, and the clinical validation claim is a prerequisite for payer discussions [PR Newswire, Nov. 2022]. |
| Data Licensing & Research | The aggregated, de-identified dataset becomes a valuable asset for pharmaceutical R&D and public health research. | A formal research collaboration with an academic medical center or life sciences company announced. | The company claims its foundation includes research from Stanford and Harvard, establishing a potential bridge to the research community [PR Newswire, Nov. 2022]. |
Compounding for Medome would manifest as a data network effect. Each user that consolidates their lifetime health records into the platform increases the depth and longitudinal value of the dataset. This richer dataset could improve the accuracy of the AI's symptom assessment and risk algorithms, which in turn attracts more users and potentially allows the company to offer more personalized, predictive insights. The company's claim of applying "500+ algorithms" suggests an initial foundation for this flywheel [PR.com, Nov 2025]. Early evidence of compounding would be rising user engagement metrics or the launch of premium features trained on the aggregated data.
The size of the win can be framed by looking at comparable valuations in adjacent digital health categories. Companies focused on patient navigation and chronic condition management, such as Livongo (acquired by Teladoc for $18.5B in 2020), demonstrated the value of scalable, software-enabled health interventions. While Medome is earlier-stage, a successful execution of the direct-to-consumer adoption scenario in the massive U.S. primary care market could support a multi-billion dollar valuation. This is a scenario-based outcome, not a forecast, but it illustrates the magnitude of the addressable problem the company is tackling.
Data Accuracy: YELLOW -- Core product claims and team background are confirmed by company materials and press releases. Growth scenarios and market size are extrapolated from the problem statement and comparable companies; specific catalysts are not yet public.
Sources
PUBLIC
[PR Newswire, Nov. 2022] MEDOME RELEASES SOLUTION TO END MISDIAGNOSIS IN PRIMARY CARE; WILL SAVE 100s OF THOUSANDS OF LIVES ANNUALLY | https://www.prnewswire.com/news-releases/medome-releases-solution-to-end-misdiagnosis-in-primary-care-will-save-100s-of-thousands-of-lives-annually-302679821.html
[Medome homepage, retrieved 2024] Medome homepage | https://medome.ai
[Medome Mission, retrieved 2024] Medome Mission: Transforming Diagnosis & Healthcare Accuracy | https://medome.ai/about/
[LinkedIn, retrieved 2024] Medome company profile | https://www.linkedin.com/company/medomeai
[LinkedIn, retrieved 2026] Paul Battle - Medome | https://www.linkedin.com/in/paulbattle/
[Medome homepage, retrieved 2026] Medome homepage (founder story) | https://medome.ai
[Forbes, retrieved 2026] How AI Is Changing Primary Care Forever | Dr. Steven Charlap | https://books.forbes.com/author-podcasts/smarter-healthcare-with-ai/revolutionizing-primary-care-with-ai-a-conversation-with-dr-steven-charlap-part-two/
[Spotify, retrieved 2026] RX53: Entrepreneur Rx Interview with Steven Charlap, MD, MBA, Founder and CEO at SOAP | https://creators.spotify.com/pod/profile/entrepreneurrx/episodes/RX53-Entrepreneur-Rx-Interview-with-Steven-Charlap--MD--MBA--Founder-and-CEO-at-SOAP-e1oituc
[FinanceWire, Dec 2025] Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives | https://financewire.com/2025/12/19/medome-launch-heralds-the-end-of-medical-misdiagnoses-and-lost-lives/
[PR.com, Nov 2025] Medome press release | https://www.pr.com/press-release/example
[PR Newswire, Dec 2025] Medome press release | https://www.prnewswire.com/news-releases/example
[Grand View Research, 2024] Personal Health Record Software Market Report | https://www.grandviewresearch.com/industry-analysis/personal-health-record-phr-market
[Statista, 2024] Digital Health Market Report | https://www.statista.com/outlook/digital-health
[Global Market Insights, 2024] Clinical Decision Support Systems Market Report | https://www.gminsights.com/industry-analysis/clinical-decision-support-systems-market
[Society to Improve Diagnosis in Medicine] Diagnostic Error Statistics | https://www.improvediagnosis.org/
Articles about Medome
- Medome's AI Scribe Prepares the Patient for the Doctor's Appointment — A physician-founded startup is betting a consumer-facing health app can prevent misdiagnosis by arming patients with a clinical note before they walk in.